- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06279507
Efficacy of Hyaluronic Acid Injection in Knee Osteoarthritis
The Efficacy of Hyaluronic Acid Injection as an Adjunctive Treatment After Intraarticular Low-dose Glucocorticoid Injection for Symptomatic Knee Osteoarthritis: A Multicenter Randomized, Controlled, Double-blinded Study
The aim of this clinical trial study is to compare the efficacy of Hyaluronic injection in patients with symptomatic knee osteoarthritis. The main questions it aims to answer are:
- Is Hyaluronic acid injection improve pain symptom, joint stiffness, and joint function in patients with knee osteoarthritis
- Is Hyaluronic acid injection improve knee performance status and health-related quality of life in patients with knee osteoarthritis
Participants will be allocated to receive one treatments; either Hyaluronic acid or normal saline injections after receiving glucocorticoid injection.
Researchers will compare the Hyaluronic acid with normal saline injection to see if the former show superior effect in terms of pain, joint stiffness, function, as well as health-related quality of life comparing with placebo.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Participants who had been diagnosed with knee osteoarthritis according to American College of Rheumatology (ACR) criteria will be enrolled in this study. After the participants receive the information and consent to participate in this study, they will be examined their affected knee by the co-researchers. Ten-milligrams of Triamcinolone will be injected intra-articular into knee joint.
Two-to-four weeks later, the participants will be evaluated for knee pain, stiffness, function and quality of life, as well as knee performance status. Participants whose their knee joint absence of effusion will be allocated in to one treatment group; either Hyaluronic acid or normal saline. After injection, participants will be scheduled for the follow-up visit in 12 and 24 weeks later. In each follow-up visit, they will be evaluated for joint pain, stiffness, function and quality of life, as well as analgesic use and adverse reaction form treatment.
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Nis Okuma, Medical
- Phone Number: 669-24759900
- Email: nitzumo@gmail.com
Study Locations
-
-
-
Bangkok, Thailand, 10400
- Recruiting
- Phramongkutklao Hospital
-
Contact:
- Suthee Panichkul
- Phone Number: 93681 6623547600
- Email: suthee99@yahoo.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- All participants who had been diagnosed as knee osteoarthritis according to ACR criteria with symptom of knee pain
- Pain visual analog scare of 4 or higher
Exclusion Criteria: Participants who have
- Cognitive impairment
- History of aller to Hyaluronic acid or its component
- History of knee arthropathy
- Concomitant with inflammatory arthritis
- Serious comorbidities or bedridden status
- Current pregnancy or lactation
- Currently use of symptomatic slow acting drugs for osteoarthritis (SYSADOA)
- Communication problem
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Hyaluronic acid
Hyaluronic acid, Ostenil Plus, 2 mL (40 mg) will be injected once afer 2-4 week of glucocorticoid injection
|
Sodium hyaluronate 2% (40 mg/2 mL), with molecular weight of 1-2 million dalton Other active ingredient : Mannitol 0.5% Preparation : Pre-filled syringe
Other Names:
10 mg of triamcinolone acetonide will be injected to all participants before the specified intervention
|
Placebo Comparator: Normal saline
Two-millilitres of normal saline will be injected once after 2-4 weeks of glucocorticoid injection
|
10 mg of triamcinolone acetonide will be injected to all participants before the specified intervention
0.9% sodium chloride 2 mL prepared in plastic syringe
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain outcome measurement
Time Frame: 12 and 24 weeks after injection
|
The comparison between Hyaluronic acid and normal saline injection in the change of joint pain after the injection, by using visual analog scale and pain domain assessment in Western Ontario and McMaster University (WOMAC) scale (scale 0-10, which higher scale reflects worse symptom)
|
12 and 24 weeks after injection
|
Joint stiffness and function measurement
Time Frame: 12 and 24 weeks after injection
|
The comparison between Hyaluronic acid and normal saline injection in the change of joint stiffness and function after the injection, by using WOMAC scale (scale 0-10, which higher scale reflects worse symptom or function)
|
12 and 24 weeks after injection
|
Overall symptom assessment
Time Frame: 12 and 24 weeks after injection
|
The comparison between Hyaluronic acid and normal saline injection in the change of overall symptom after the injection, by using patient's global assessment (scale 0-10, which higher scale reflects worse condition)
|
12 and 24 weeks after injection
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Knee performance evaluation
Time Frame: 12 and 24 weeks after injection
|
The comparison between Hyaluronic acid and normal saline injection in the change of knee performance status after the injection, assessed by Time Up and Go test
|
12 and 24 weeks after injection
|
Quality of life assessment
Time Frame: 12 and 24 weeks after injection
|
The comparison between Hyaluronic acid and normal saline injection in the change of health-related quality of life assessed by EuroQol group - 5 Dimensions - 5 Levels (EQ-5D-5L) tool (scale 0-100, which higher scale reflects better health)
|
12 and 24 weeks after injection
|
Collaborators and Investigators
Investigators
- Principal Investigator: Nis Okuma, Medical, Phramongkutklao College of Medicine and Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pain
- Neurologic Manifestations
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Arthritis
- Osteoarthritis
- Arthralgia
- Osteoarthritis, Knee
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Immunosuppressive Agents
- Immunologic Factors
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Protective Agents
- Adjuvants, Immunologic
- Viscosupplements
- Triamcinolone
- Triamcinolone Acetonide
- Triamcinolone hexacetonide
- Triamcinolone diacetate
- Hyaluronic Acid
Other Study ID Numbers
- PMK-00007
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Quality of Life
-
Assiut UniversityUnknownImproving Quality of LifeEgypt
-
Children's National Research InstituteRecruitingProfessional Quality of LifeUnited States
-
Istituto Ortopedico RizzoliUniversity of BolognaActive, not recruitingImprove Quality of LifeItaly
-
B. Braun Medical SAUnknownQuality of Life of Colostomized Patient
-
Mattu UniversityCompletedBreif Description: Patients' Quality of Life ofEthiopia
-
University of South CarolinaNational Institute on Minority Health and Health Disparities (NIMHD)RecruitingHealth Related Quality of LifeUnited States
-
PharmanexSprim Advanced Life SciencesCompletedHealth-related Quality of LifeUnited States
-
Linkoeping UniversityRecruiting
-
South Valley UniversityActive, not recruitingDeterminants of Health-related Quality of Life for Patients After Renal Lithotripsy: PNL Versus RIRSHealth Related Quality of LifeEgypt
-
Region VästmanlandUnknownHealth Related Quality of Life
Clinical Trials on Sodium Hyaluronate
-
Democritus University of ThraceGeorge Papanicolaou Hospital; Naval Hospital, Athens; Athinaiki General ClinicCompleted
-
DiscGenics, Inc.CTI Clinical Trial and Consulting ServicesCompletedDegenerative Disc DiseaseUnited States
-
Peking University People's HospitalUnknown
-
Second Affiliated Hospital of Xi'an Jiaotong UniversityUnknownDry Eye | Cataract SenileChina
-
Ferring PharmaceuticalsCompletedInvestigation of 1.2% Sodium Hyaluronate for Treatment of Painful Chronic Osteoarthritis of the KneeOsteoarthritis of the KneeUnited States
-
Laboratorios Sophia S.A de C.V.Completed
-
Laboratorios Sophia S.A de C.V.Completed
-
Hasanuddin UniversityCompleted
-
Laboratorios Sophia S.A de C.V.Active, not recruitingDry Eye SyndromesMexico